| 1 |
Carr HS, Zuo Y, Frost JA. The Wnt pathway protein Dvl1 targets Somatostatin receptor 2 for lysosome-dependent degradation. J Biol Chem 2023;:104645. [PMID: 36965619 DOI: 10.1016/j.jbc.2023.104645] [Reference Citation Analysis]
|
| 2 |
Konsek-Komorowska SJ, Pęczkowska M, Kolasińska-Ćwikła AD, Cichocki A, Konka M, Roszkowska-Purska K, Ćwikła JB. Analysis of Patients with NET G1/G2 Neuroendocrine Tumors of the Small Intestine in the Course of Carcinoid Heart Disease-A Retrospective Study. J Clin Med 2023;12. [PMID: 36769439 DOI: 10.3390/jcm12030790] [Reference Citation Analysis]
|
| 3 |
Zhao J, Wang S, Markison S, Kim SH, Han S, Chen M, Kusnetzow AK, Rico-Bautista E, Johns M, Luo R, Struthers RS, Madan A, Zhu Y, Betz SF. Discovery of Paltusotine (CRN00808), a Potent, Selective, and Orally Bioavailable Non-peptide SST2 Agonist. ACS Med Chem Lett 2023;14:66-74. [PMID: 36655128 DOI: 10.1021/acsmedchemlett.2c00431] [Reference Citation Analysis]
|
| 4 |
Yoshida T, Yaegashi H, Toriumi R, Kadomoto S, Iwamoto H, Izumi K, Kadono Y, Ikeda H, Mizokami A. Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report. Front Oncol 2022;12:912490. [DOI: 10.3389/fonc.2022.912490] [Reference Citation Analysis]
|
| 5 |
Mohajeri-tehrani MR, Ebrahimpur M, Nasseri-moghaddam S, Tavangar S, Sani MP, Zandi A, Shadmehr MB. Medical management of pancreatic neuroendocrine tumors in patients with MEN 1: case report. J Diabetes Metab Disord. [DOI: 10.1007/s40200-022-01067-3] [Reference Citation Analysis]
|
| 6 |
Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G, Wang X, Wang R, Fu C. Therapeutic peptides: current applications and future directions. Sig Transduct Target Ther 2022;7. [DOI: 10.1038/s41392-022-00904-4] [Cited by in Crossref: 40] [Cited by in F6Publishing: 48] [Article Influence: 40.0] [Reference Citation Analysis]
|
| 7 |
Bari ABA, Samuel PJ. Therapeutic Proteins Used in Human Pancreatic Disease. Therapeutic Proteins Against Human Diseases 2022. [DOI: 10.1007/978-981-16-7897-4_8] [Reference Citation Analysis]
|
| 8 |
Subash N, Papali MM, Bahadur KP, Avanthika C, Jhaveri S, Thannir S, Joshi M, Valisekka SS. Recent Advances in the Diagnosis and Management of Carcinoid Syndrome. Dis Mon 2021;:101304. [PMID: 34972546 DOI: 10.1016/j.disamonth.2021.101304] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 9 |
Emanuel O, Liu J, Schartinger VH, Nei WL, Chan YY, Tsang CM, Riechelmann H, Masterson L, Haybaeck J, Oppermann U, Willems SM, Ooft ML, Wollmann G, Howard D, Vanhaesebroeck B, Lund VJ, Royle G, Chua MLK, Lo KW, Busson P, Lechner M. SSTR2 in Nasopharyngeal Carcinoma: Relationship with Latent EBV Infection and Potential as a Therapeutic Target. Cancers (Basel) 2021;13:4944. [PMID: 34638429 DOI: 10.3390/cancers13194944] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 10 |
Carr HS, Chang JT, Frost JA. The PDZ Domain Protein SYNJ2BP Regulates GRK-Dependent Sst2A Phosphorylation and Downstream MAPK Signaling. Endocrinology 2021;162. [PMID: 33313679 DOI: 10.1210/endocr/bqaa229] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 11 |
Polcz M, Schlegel C, Edwards GC, Wang F, Tan M, Kiernan C, Solórzano CC, Idrees K, Parikh A, Bailey CE. Primary Tumor Resection Offers Survival Benefit in Patients with Metastatic Midgut Neuroendocrine Tumors. Ann Surg Oncol 2020;27:2795-803. [PMID: 32430752 DOI: 10.1245/s10434-020-08602-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 12 |
Pignata SA, Ferrantelli A, Baldari S. Peptide receptor radionuclide therapy plus somatostatin analogues for a neuroendocrine tumour combined and maintenance treatment. Clin Transl Imaging 2019;7:373-6. [DOI: 10.1007/s40336-019-00342-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 13 |
Saif MW, Parikh R, Ray D, Kaye JA, Kurosky SK, Thomas K, Ramirez RA, Halfdanarson TR, Beveridge TJR, Mirakhur B, Nagar SP, Soares HP. Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors. J Gastrointest Oncol 2019;10:674-87. [PMID: 31392048 DOI: 10.21037/jgo.2019.03.11] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 14 |
Lopez CL, Joos B, Bartsch DK, Manoharan J, Albers M, Slater EP, Bollmann C, Roth S, Bayer A, Fendrich V. Chemoprevention with Somatuline© Delays the Progression of Pancreatic Neuroendocrine Neoplasms in a Mouse Model of Multiple Endocrine Neoplasia Type 1 (MEN1). World J Surg 2019;43:831-8. [PMID: 30600364 DOI: 10.1007/s00268-018-4839-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 15 |
Vesterinen T, Leijon H, Mustonen H, Remes S, Knuuttila A, Salmenkivi K, Vainio P, Arola J, Haglund C. Somatostatin Receptor Expression Is Associated With Metastasis and Patient Outcome in Pulmonary Carcinoid Tumors. J Clin Endocrinol Metab 2019;104:2083-93. [PMID: 30657933 DOI: 10.1210/jc.2018-01931] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 16 |
Štaka I, Cadete A, Surikutchi BT, Abuzaid H, Bradshaw TD, Alonso MJ, Marlow M. A novel low molecular weight nanocomposite hydrogel formulation for intra-tumoural delivery of anti-cancer drugs. Int J Pharm 2019;565:151-61. [PMID: 31029659 DOI: 10.1016/j.ijpharm.2019.04.070] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 17 |
Klink AJ, Feinberg B, Yu HT, Ray D, Pulgar S, Phan A, Vinik A. Patterns of Care Among Real-World Patients with Metastatic Neuroendocrine Tumors. Oncologist 2019;24:1331-9. [PMID: 31015313 DOI: 10.1634/theoncologist.2018-0798] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 18 |
Ito T, Lee L, Jensen RT. Carcinoid-syndrome: recent advances, current status and controversies. Curr Opin Endocrinol Diabetes Obes 2018;25:22-35. [PMID: 29120923 DOI: 10.1097/MED.0000000000000376] [Cited by in Crossref: 58] [Cited by in F6Publishing: 65] [Article Influence: 14.5] [Reference Citation Analysis]
|
| 19 |
Papanagnou P, Papadopoulos GE, Stivarou T, Pappas A. Toward fully exploiting the therapeutic potential of marketed pharmaceuticals: the use of octreotide and chloroquine in oncology. Onco Targets Ther 2019;12:319-39. [PMID: 30643430 DOI: 10.2147/OTT.S182685] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 20 |
Herrera-Martínez AD, Gahete MD, Sánchez-Sánchez R, Alors-Perez E, Pedraza-Arevalo S, Serrano-Blanch R, Martínez-Fuentes AJ, Gálvez-Moreno MA, Castaño JP, Luque RM. Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Novel Potential Biomarker in Gastroenteropancreatic Neuroendocrine Tumors. Clin Transl Gastroenterol 2018;9:196. [PMID: 30297816 DOI: 10.1038/s41424-018-0058-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 21 |
Moody TW, Ramos-Alvarez I, Jensen RT. Neuropeptide G Protein-Coupled Receptors as Oncotargets. Front Endocrinol (Lausanne) 2018;9:345. [PMID: 30008698 DOI: 10.3389/fendo.2018.00345] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 22 |
Jiao X, Pulgar S, Boyd M, Braiteh F, Mirakhur B, Pitman Lowenthal S, Fox P, Frytak J, Cox D, Paulson AS. Treatment Patterns and Clinical Outcomes in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated in the Community Practice Setting in the United States. Pancreas 2018;47:173-82. [PMID: 29206668 DOI: 10.1097/MPA.0000000000000955] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 23 |
Cuyle PJ, Prenen H. Practical management of toxicities associated with targeted therapies for advanced gastroenteropancreatic neuroendocrine tumors. Ann Gastroenterol. 2018;31:140-150. [PMID: 29507461 DOI: 10.20524/aog.2018.0224] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 24 |
Jensen RT. Gastrointestinal Neuroendocrine Tumor Syndromes (GI NETS). Encyclopedia of Endocrine Diseases 2018. [DOI: 10.1016/b978-0-12-801238-3.95870-7] [Reference Citation Analysis]
|
| 25 |
Herrera-Martínez AD, Gahete MD, Pedraza-Arevalo S, Sánchez-Sánchez R, Ortega-Salas R, Serrano-Blanch R, Luque RM, Gálvez-Moreno MA, Castaño JP. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors. Endocrine 2018;59:426-37. [PMID: 29196939 DOI: 10.1007/s12020-017-1482-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 26 |
Giraldo M, Harle C, Lopera-velásquez LM, Dobkowsky W. Surgical treatment of carcinoid syndrome metastatic disease: Partial hepatectomy with veno-venous bypass and subsequent tricuspid valve replacement. Case report. Colombian Journal of Anesthesiology 2017;45:344-348. [DOI: 10.1016/j.rcae.2017.08.011] [Reference Citation Analysis]
|
| 27 |
Giraldo M, Harle C, Lopera-velásquez LM, Dobkowsky W. Tratamiento quirúrgico de la enfermedad metastásica del síndrome carcinoide: hepatectomía parcial usando un bypass veno-venoso y posterior cambio valvular tricúspide. Reporte de caso. Revista Colombiana de Anestesiología 2017;45:344-348. [DOI: 10.1016/j.rca.2017.06.004] [Reference Citation Analysis]
|
| 28 |
Giraldo M, Harle C, Lopera-velásquez LM, Dobkowsky W. Surgical treatment of carcinoid syndrome metastatic disease: Partial hepatectomy with veno-venous bypass and subsequent tricuspid valve replacement. Case report☆. Colombian Journal of Anesthesiology 2017;45:344-348. [DOI: 10.1097/01819236-201710000-00011] [Reference Citation Analysis]
|
| 29 |
Ortendahl JD, Pulgar SJ, Mirakhur B, Cox D, Bentley TG, Phan AT. Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals. Clinicoecon Outcomes Res 2017;9:495-503. [PMID: 28860831 DOI: 10.2147/CEOR.S140866] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 30 |
Lappano R, Maggiolini M. Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts. Drugs 2017;77:951-65. [PMID: 28401445 DOI: 10.1007/s40265-017-0738-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 31 |
Dissanayake S, Denny WA, Gamage S, Sarojini V. Recent developments in anticancer drug delivery using cell penetrating and tumor targeting peptides. Journal of Controlled Release 2017;250:62-76. [DOI: 10.1016/j.jconrel.2017.02.006] [Cited by in Crossref: 166] [Cited by in F6Publishing: 175] [Article Influence: 27.7] [Reference Citation Analysis]
|
| 32 |
Ito T, Lee L, Jensen RT. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies. Expert Opin Pharmacother. 2016;17:2191-2205. [PMID: 27635672 DOI: 10.1080/14656566.2016.1236916] [Cited by in Crossref: 45] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 33 |
Hannah-Shmouni F, Stratakis CA, Koch CA. Flushing in (neuro)endocrinology. Rev Endocr Metab Disord 2016;17:373-80. [PMID: 27873108 DOI: 10.1007/s11154-016-9394-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 27] [Article Influence: 5.7] [Reference Citation Analysis]
|
